Similarity of uterine mucosa changes in patients treated by Raloxifen and Tamoxifen
(2002) In Anticancer research 22(2B). p.1121-1125- Abstract
- Background: Selective estrogen receptor modulators (SERMS) like Tamoxifen and Raloxifen are used for menopausal symptoms, prevention of cardio-vascular diseases, osteoporosis and mammary carcinoma. Tamoxifen acts as an estrogen inhibitor on the mammary gland, but stimulates postmenopausal uterine mucosa in about 25% of cases while decreasing the risk of osteoporosis. Materials, Methods and Results: In three menopausal women, 56, 79 and 62 years of age, we found uterine mucosal changes similar to what is found in Tamoxifen-treated patients. Using light microscopy and immuno-histopathological techniques, partly cystic mucosa with both atrophic and proliferating glands was found. Strong stromal proliferation was also seen with the typical... (More)
- Background: Selective estrogen receptor modulators (SERMS) like Tamoxifen and Raloxifen are used for menopausal symptoms, prevention of cardio-vascular diseases, osteoporosis and mammary carcinoma. Tamoxifen acts as an estrogen inhibitor on the mammary gland, but stimulates postmenopausal uterine mucosa in about 25% of cases while decreasing the risk of osteoporosis. Materials, Methods and Results: In three menopausal women, 56, 79 and 62 years of age, we found uterine mucosal changes similar to what is found in Tamoxifen-treated patients. Using light microscopy and immuno-histopathological techniques, partly cystic mucosa with both atrophic and proliferating glands was found. Strong stromal proliferation was also seen with the typical sharp-edged form of stromal cells and mitoses. A strong ostrogen and progesterone reaction was revealed with immuno-histopathological techniques in both gland and stromal parts. Conclusion: Taking into account the variable amount of different estrogen-receptor types in the uterine mucosa, we can not in the long run expect that no patient will react with estrogen-stimulation features on SERMs like Raloxifen. Further studies and thorough observations are needed to elucidate the true frequency of Raloxifen impact on the uterine mucosa. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/332165
- author
- Willen, R ; Willlen, H and Lindahl, Bengt LU
- organization
- publishing date
- 2002
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- histopathology, uterine mucosa, polyps, Raloxifen
- in
- Anticancer research
- volume
- 22
- issue
- 2B
- pages
- 1121 - 1125
- publisher
- International Institute of Cancer Research
- external identifiers
-
- wos:000177246300014
- scopus:0036327135
- ISSN
- 1791-7530
- language
- English
- LU publication?
- yes
- id
- f986d2b7-9dcf-47c0-9b63-628c31e03a1b (old id 332165)
- date added to LUP
- 2016-04-01 11:44:38
- date last changed
- 2022-01-26 17:34:25
@article{f986d2b7-9dcf-47c0-9b63-628c31e03a1b,
abstract = {{Background: Selective estrogen receptor modulators (SERMS) like Tamoxifen and Raloxifen are used for menopausal symptoms, prevention of cardio-vascular diseases, osteoporosis and mammary carcinoma. Tamoxifen acts as an estrogen inhibitor on the mammary gland, but stimulates postmenopausal uterine mucosa in about 25% of cases while decreasing the risk of osteoporosis. Materials, Methods and Results: In three menopausal women, 56, 79 and 62 years of age, we found uterine mucosal changes similar to what is found in Tamoxifen-treated patients. Using light microscopy and immuno-histopathological techniques, partly cystic mucosa with both atrophic and proliferating glands was found. Strong stromal proliferation was also seen with the typical sharp-edged form of stromal cells and mitoses. A strong ostrogen and progesterone reaction was revealed with immuno-histopathological techniques in both gland and stromal parts. Conclusion: Taking into account the variable amount of different estrogen-receptor types in the uterine mucosa, we can not in the long run expect that no patient will react with estrogen-stimulation features on SERMs like Raloxifen. Further studies and thorough observations are needed to elucidate the true frequency of Raloxifen impact on the uterine mucosa.}},
author = {{Willen, R and Willlen, H and Lindahl, Bengt}},
issn = {{1791-7530}},
keywords = {{histopathology; uterine mucosa; polyps; Raloxifen}},
language = {{eng}},
number = {{2B}},
pages = {{1121--1125}},
publisher = {{International Institute of Cancer Research}},
series = {{Anticancer research}},
title = {{Similarity of uterine mucosa changes in patients treated by Raloxifen and Tamoxifen}},
volume = {{22}},
year = {{2002}},
}